Polish high jumper Norbert Kobielski will not compete in the Paris Olympics after being suspended by the anti-doping agency for using a substance found in so-called designer drugs. The suspension, announced by the Athletics Integrity Unit (AIU) just three days before the start of the Olympics, cites the presence of Pentedrone norephedrine metabolite in Kobielski’s system. This substance, commonly found in recreational drugs, was detected in a test on July 15.
Official Denial and Confirmation
Despite Kobielski’s denial of any ongoing proceedings, TVP SPORT journalist Michał Chmielewski confirmed the case was under investigation, though the specific substance was initially unknown. Kobielski maintained that he was preparing for the Olympics as usual and dismissed the allegations. However, the AIU’s official statement and the confirmation from Polish Anti-Doping Agency (POLADA) head Michał Rynkowski clarified the situation.
This is Kobielski’s second anti-doping rule violation, putting him at risk of up to four years of disqualification. Rynkowski confirmed the suspension and emphasized the severity of the repeat offense. Just days before the announcement, Kobielski participated in the Olympic oath ceremony with other Polish athletes, underscoring the sudden and impactful nature of the suspension.
Impact on Olympic Dreams
Kobielski’s suspension is a significant blow to the Polish athletic team and his Olympic aspirations. As the situation unfolds, it serves as a stark reminder of the stringent anti-doping regulations in place to maintain integrity in sports. The timing of the suspension leaves little room for appeal, effectively ending Kobielski’s hopes of competing in Paris.